Jennifer Griffin - Amedisys Chief Secretary
| AMED Stock | USD 92.38 0.39 0.42% |
Executive
Jennifer Griffin is Chief Secretary of Amedisys
| Address | 3854 American Way, Baton Rouge, LA, United States, 70816 |
| Phone | 225 292 2031 |
| Web | https://www.amedisys.com |
Jennifer Griffin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jennifer Griffin against Amedisys stock is an integral part of due diligence when investing in Amedisys. Jennifer Griffin insider activity provides valuable insight into whether Amedisys is net buyers or sellers over its current business cycle. Note, Amedisys insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amedisys'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jennifer Griffin over two months ago Disposition of 3507 shares by Jennifer Griffin of Amedisys at 89.96 subject to Rule 16b-3 |
Amedisys Management Efficiency
The company has return on total asset (ROA) of 0.0624 % which means that it generated a profit of $0.0624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0332 %, meaning that it created $0.0332 on every $100 dollars invested by stockholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. At present, Amedisys' Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.04, whereas Return On Assets are forecasted to decline to 0.01. At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 92.4 M, whereas Net Tangible Assets are projected to grow to (288.1 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matt Huray | InnovAge Holding Corp | N/A | |
| Danielle Burkhalter | Surgery Partners | 40 | |
| Femi MD | Option Care Health | N/A | |
| Roman Fry | Option Care Health | N/A | |
| CPA CFA | Acadia Healthcare | N/A | |
| Cliff Blessing | Addus HomeCare | 44 | |
| Elissa Charbonneau | Encompass Health Corp | 64 | |
| Brett Bearfield | Acadia Healthcare | N/A | |
| Lynette CPA | Pennant Group | 47 | |
| Matthew Klein | Universal Health Services | N/A | |
| Bill Priest | Acadia Healthcare | N/A | |
| Luke Whitworth | Option Care Health | 44 | |
| Roberton Stevenson | Addus HomeCare | 44 | |
| Heather CPA | Acadia Healthcare | 53 | |
| Ryan Solomon | Enhabit | N/A | |
| Victor Radina | Universal Health Services | N/A | |
| Nicole DAmato | InnovAge Holding Corp | 46 | |
| Patrick Esq | Healthcare Services Group | 50 | |
| Maritza DeGagne | Option Care Health | N/A | |
| Dylan Black | Enhabit | 55 | |
| Dustin Lee | InnovAge Holding Corp | N/A | |
Management Performance
| Return On Equity | 0.0332 | ||||
| Return On Asset | 0.0624 |
Amedisys Leadership Team
Elected by the shareholders, the Amedisys' board of directors comprises two types of representatives: Amedisys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amedisys. The board's role is to monitor Amedisys' management team and ensure that shareholders' interests are well served. Amedisys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amedisys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael North, Senior Vice President - Operations | ||
| John Nugent, Chief Officer | ||
| Pete Hartley, CTO Systems | ||
| Kendra Kimmons, VP Relations | ||
| Jennifer Griffin, Chief Secretary | ||
| Janet Britt, VP Collections | ||
| Francis Mayer, Senior Development | ||
| Keith Blanchard, Acting Officer | ||
| Richard Ashworth, CEO President | ||
| Scott CPA, COO, VP | ||
| Allyson Guidroz, Chief Officer | ||
| Scott Ginn, Chief Accounting Officer | ||
| Denise Bohnert, Chief Officer | ||
| Paul Kusserow, CEO and President and Director | ||
| Caitlin Franklin, Acting Officer | ||
| Nick Muscato, Vice President of Strategic Finance | ||
| Adam Holton, Chief Officer |
Amedisys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amedisys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0332 | ||||
| Return On Asset | 0.0624 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 3.19 B | ||||
| Shares Outstanding | 32.81 M | ||||
| Shares Owned By Insiders | 2.09 % | ||||
| Shares Owned By Institutions | 91.48 % | ||||
| Number Of Shares Shorted | 2.74 M | ||||
| Price To Earning | 15.03 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.35) | Earnings Share 1.31 | Revenue Per Share | Quarterly Revenue Growth 0.048 | Return On Assets |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.